Zanubrutinib with chemo for mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (bendamustine and rituximab) for people newly diagnosed with mantle cell lymphoma. It is designed for older adults, those with certain genetic changes (TP53), or those who cannot tolerate standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma that was just diagnosed.
- You are 65 years or older, or have a specific genetic change (TP53 alteration), or are under 65 but cannot tolerate chemotherapy.
- Your kidneys are working well enough (based on blood tests).
- Your heart pumps at least half the normal amount (LVEF 50% or higher).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of targeted drugs (zanubrutinib plus other medicines) in people newly diagnosed with mantle cell lymphoma. It aims to see how effective and safe these drugs are for different age groups, possibly helping control the cancer.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
This trial tests a new combination of three targeted therapies for people newly diagnosed with a high-risk form of mantle cell lymphoma (MCL), a rare blood cancer. The goal is to see if this combination is safe and effective in shrinking or eliminating the cancer.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Hear when a new Lymphoma, Mantle-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.